FARIS TAHSIN: Open Payments
NPI 1255836672 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,838 in 132 payments from 17 companies in 2025. Trend: 2023 $313 · 2024 $1,576 · 2025 $2,838
Food & beverage: $2,838
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 16 | $625 |
| Otsuka America Pharmaceutical, Inc. | 25 | $418 |
| E.R. Squibb & Sons, L.L.C. | 12 | $284 |
| Alkermes, Inc. | 9 | $240 |
| Teva Pharmaceuticals USA, Inc. | 11 | $237 |
| Janssen Pharmaceuticals, Inc | 9 | $199 |
| ABBVIE INC. | 10 | $161 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $152 |
| Vanda Pharmaceuticals Inc. | 4 | $120 |
| Axsome Therapeutics, Inc. | 5 | $111 |
Products named: INGREZZA, REXULTI, COBENFY, ARISTADA, VRAYLAR, AUSTEDO XR, CAPLYTA, SPRAVATO.
Industry payments across NV — which companies pay providers there.
